Biblio
.
Evaluating the cost-effectiveness of [F]FDG-PET/CT for investigation of persistent or recurrent neutropenic fever in high-risk haematology patients. Cancer Imaging. 2023;23(1):119.
If we do not count it, it does not count: ethnicity in allogeneic haemopoietic stem cell transplant in Australia. Intern Med J. 2023.
Long-term effectiveness of eculizumab: Data from the International PNH Registry. Eur J Haematol. 2023.
. An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. Transplant Cell Ther. 2022.
[F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Haematol. 2022.
Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial. Lancet Haematol. 2022;9(9):e648-e659.
Suitability of haematopoietic cell donors: updated consensus recommendations from the WBMT standing committee on donor issues. Lancet Haematol. 2022;9(8):e605-e614.
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med. 2021;384(11):1028-1037.
The impact of COVID-19 on the provision of donor hematopoietic stem cell products worldwide: collateral damage. Bone Marrow Transplant. 2020.
. The QuantiFERON Monitor Assay is predictive of infection post allogeneic hematopoietic cell transplant. Transpl Infect Dis. 2020:e13260.
. Real-world issues and potential solutions in HCT during the COVID-19 pandemic: Perspectives from the WBMT and the CIBMTR's Health Services and International Studies Committee. Biol Blood Marrow Transplant. 2020.
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. N Engl J Med. 2020.
Is there no place like home for an allogeneic stem cell transplant?. Bone Marrow Transplant. 2020.
. Global Use of Peripheral Blood vs Bone Marrow as Source of Stem Cells for Allogeneic Transplantation in Patients With Bone Marrow Failure. JAMA. 2016;315(2):198-200.
. Safety of Living Donation of Hematopoietic Stem Cells. Transplantation. 2016.
.